SEC Form 3 filed by InMode Ltd.
$INMD
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/29/2025 | Buy → Neutral | BTIG Research | |
| 4/28/2025 | $22.00 → $16.00 | Outperform → Neutral | Robert W. Baird |
| 10/17/2024 | $25.00 | Buy | BTIG Research |
| 7/23/2024 | $21.00 → $19.00 | Buy → Hold | Jefferies |
| 11/3/2023 | $52.00 → $24.00 | Buy → Neutral | UBS |
| 10/13/2023 | $55.00 → $22.00 | Buy → Hold | Canaccord Genuity |
| 3/29/2023 | $40.00 | Buy | UBS |
| 2/17/2023 | Buy → Hold | Needham |
Questions Whether Management is Steering Reported Results to Fit the CEO’s Lowball Bid Demands the Group Led by CEO Moshe Mizrahy Cure Its Disclosure Deficiencies Calls on the Board to Reschedule the Annual General Meeting to Allow Shareholders to Review Full Record and Bring Their Own Resolutions Steel Partners Holdings L.P. (together with its affiliates, "Steel"), a significant, long-standing shareholder of InMode Ltd. ("InMode" or the "Company") (NASDAQ:INMD), today issued a letter to the Board of Directors (the "Board") of the Company. The full text of the letter is below. July 16, 2026 VIA ELECTRONIC MAIL InMode Ltd. Tavor Building, Sha’ar Yokneam P.O. Box 533 Yokneam 20692
YOKNEAM, Israel, July 13, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter of 2026 before the Nasdaq market opens on Wednesday, August 5, 2026. InMode is currently finalizing its financial results for the second quarter of 2026. While complete financial information and operating data are not yet available, set forth below are certain preliminary results such period, subject to final adjustments and other developments that may arise between now and the time such financial results a
YOKNEAM, Israel, July 10, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) (the "Company") confirmed that its Board of Directors (the "Board") has received the unsolicited letter and acquisition proposal from Steel Partners Holdings L.P. dated July 9, 2026. The Special Committee comprised solely of the independent directors of the Board (the "Special Committee"), together with its legal and financial advisors, will carefully review the proposal consistent with its fiduciary duties.The Special Committee remains committed to acting in the best interests of all shareholders. The Special Committee does not intend to comment further at this time.About InMode Ltd.The Company is a leading global prov
BTIG Research downgraded InMode from Buy to Neutral
Robert W. Baird downgraded InMode from Outperform to Neutral and set a new price target of $16.00 from $22.00 previously
BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00
3 - InMode Ltd. (0001742692) (Issuer)
3 - InMode Ltd. (0001742692) (Issuer)
3 - InMode Ltd. (0001742692) (Issuer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
Conexeu Sciences just 3D-bioprinted a new tissue matrix to one of the most respected regenerative medicine institutes in the world. For investors watching how breast reconstruction — and the wider field of tissue regeneration — evolves, the next 18 months matter. NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary — For more than fifty years, breast reconstruction has mostly meant one thing: replacement. A silicone shell, filled with gel, designed to restore shape and volume, none of them designed to regenerate the breast's own living tissue. That gap has consequences. Roughly two-thirds of the more than 100,000 women in the United States who undergo a mastectomy ea
YOKNEAM, Israel, May 20, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode" or the "Company"), a leading global provider of innovative medical technologies, today announced the appointment of Dr. Shlomo Nass as Chairman of the Company's Board of Directors (the "Board") and Moshik Itzkovich as Chief Financial Officer, effective immediately. Dr. Nass succeeds Dr. Michael Anghel, who retired earlier this month, and will lead the Board in supporting the Company's long-term strategic growth and governance priorities. Dr. Nass brings decades of expertise in corporate law, accoun
IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America. Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market shar
Questions Whether Management is Steering Reported Results to Fit the CEO’s Lowball Bid Demands the Group Led by CEO Moshe Mizrahy Cure Its Disclosure Deficiencies Calls on the Board to Reschedule the Annual General Meeting to Allow Shareholders to Review Full Record and Bring Their Own Resolutions Steel Partners Holdings L.P. (together with its affiliates, "Steel"), a significant, long-standing shareholder of InMode Ltd. ("InMode" or the "Company") (NASDAQ:INMD), today issued a letter to the Board of Directors (the "Board") of the Company. The full text of the letter is below. July 16, 2026 VIA ELECTRONIC MAIL InMode Ltd. Tavor Building, Sha’ar Yokneam P.O. Box 533 Yokneam 20692
YOKNEAM, Israel, July 13, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter of 2026 before the Nasdaq market opens on Wednesday, August 5, 2026. InMode is currently finalizing its financial results for the second quarter of 2026. While complete financial information and operating data are not yet available, set forth below are certain preliminary results such period, subject to final adjustments and other developments that may arise between now and the time such financial results a
YOKNEAM, Israel, May 6, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter of 2026. First Quarter 2026 Highlights:● Quarterly GAAP revenues of $82.0 million, compared to $77.9 million in the first quarter of 2025.● Quarterly revenues from consumables and service of $21.4 million, an increase of 6% compared to the first quarter of 2025.● GAAP operating income of $10.1 million, *non-GAAP operating income of $14.0 million.● Total cash po
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G - InMode Ltd. (0001742692) (Subject)